We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Audentes Therapeutics (BOLD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Audentes Therapeutics is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BOLD is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BOLD's full-year earnings has moved 6.80% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BOLD has returned 30.08% so far this year. Meanwhile, the Medical sector has returned an average of 2.81% on a year-to-date basis. This means that Audentes Therapeutics is performing better than its sector in terms of year-to-date returns.
Breaking things down more, BOLD is a member of the Medical - Biomedical and Genetics industry, which includes 281 individual companies and currently sits at #109 in the Zacks Industry Rank. This group has gained an average of 1.16% so far this year, so BOLD is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to BOLD as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Audentes Therapeutics (BOLD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Audentes Therapeutics is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BOLD is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BOLD's full-year earnings has moved 6.80% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BOLD has returned 30.08% so far this year. Meanwhile, the Medical sector has returned an average of 2.81% on a year-to-date basis. This means that Audentes Therapeutics is performing better than its sector in terms of year-to-date returns.
Breaking things down more, BOLD is a member of the Medical - Biomedical and Genetics industry, which includes 281 individual companies and currently sits at #109 in the Zacks Industry Rank. This group has gained an average of 1.16% so far this year, so BOLD is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to BOLD as it looks to continue its solid performance.